Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

NCT03939234 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

COMBINATION_PRODUCT: PD-L1, PD-L2 peptides with Montanide ISA51

Sponsor

Lars Møller Pedersen

Collaborators

[object Object]